Codexis
Protein engineering company delivering enzymatic solutions for RNA and pharma manufacturing.
Founded
2002Protein engineering company delivering enzymatic solutions for RNA and pharma manufacturing.
Codexis commercial offerings center on three buyer-facing families: RNA Manufacturing Services built on ECO Synthesis enzymatic synthesis, Pharma Biocatalysis for small-molecule API enzyme development, and Molecular Biology and Diagnostic Enzymes for specialty assay and diagnostic reagents.
The ECO Synthesis Manufacturing Platform is the flagship RNA product path, combining ligation-based and sequential enzymatic synthesis to improve yield, impurity control, and sustainability versus traditional solid-phase oligonucleotide synthesis.
Codexis competitive strength is its CodeEvolver protein-engineering stack that combines bioinformatics, machine learning, and high-throughput screening to create process-ready enzymes. That platform history supports multi-ton biocatalysis and purpose-built enzymes for nucleic-acid synthesis.
In RNA manufacturing, ECO Synthesis differentiates from solid-phase chemistry by targeting higher purity, stereochemical control, and greener scale-up as siRNA programs move into larger indications that demand commercial-scale supply.
Codexis remains loss-making on a quarterly basis and continues to fund platform scale-up through equity offerings and debt capacity, which can dilute shareholders and pressure the share price during commercialization delays. Cash runway guidance into 2027 depends on executing partnerships and controlling capital projects such as the ECO GMP facility retrofit.
Adoption of enzymatic oligonucleotide manufacturing also faces customer validation, regulatory acceptance, and competition from entrenched solid-phase CDMO capacity, so revenue conversion from evaluation agreements can take multiple development cycles.